Alex Thompson
Stock Analyst at Stifel
(1.79)
# 3,247
Out of 4,944 analysts
35
Total ratings
53.57%
Success rate
-5.46%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Buy | $212 → $254 | $191.15 | +32.88% | 3 | Aug 8, 2025 | |
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $7.64 | +187.96% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $40.74 | +35.00% | 1 | May 20, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $22 → $23 | $18.05 | +27.42% | 3 | May 2, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $9.08 | +296.69% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $30.09 | +99.40% | 1 | Mar 25, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $15.30 | +220.26% | 1 | Oct 11, 2024 | |
| ARGX argenx SE | Maintains: Buy | $485 → $500 | $646.60 | -22.67% | 4 | Jun 24, 2024 | |
| SYRE Spyre Therapeutics | Reiterates: Buy | $36 → $54 | $17.40 | +210.34% | 2 | Mar 26, 2024 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | $44 | $20.86 | +110.98% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $2 | $2.85 | -29.82% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $55.65 | +23.99% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $1.70 | -41.18% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $18.86 | +112.15% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $10.60 | +2,918.87% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $15.89 | +113.97% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.60 | +1,962.50% | 1 | Dec 14, 2022 |
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $212 → $254
Current: $191.15
Upside: +32.88%
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $7.64
Upside: +187.96%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $40.74
Upside: +35.00%
Travere Therapeutics
May 2, 2025
Maintains: Hold
Price Target: $22 → $23
Current: $18.05
Upside: +27.42%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $9.08
Upside: +296.69%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $30.09
Upside: +99.40%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $15.30
Upside: +220.26%
argenx SE
Jun 24, 2024
Maintains: Buy
Price Target: $485 → $500
Current: $646.60
Upside: -22.67%
Spyre Therapeutics
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $17.40
Upside: +210.34%
Dianthus Therapeutics
Feb 15, 2024
Initiates: Buy
Price Target: $44
Current: $20.86
Upside: +110.98%
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $2.85
Upside: -29.82%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $55.65
Upside: +23.99%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $1.70
Upside: -41.18%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $18.86
Upside: +112.15%
Aug 9, 2023
Initiates: Buy
Price Target: $320
Current: $10.60
Upside: +2,918.87%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $15.89
Upside: +113.97%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.60
Upside: +1,962.50%